ANI Pharmaceuticals Company Profile (NASDAQ:ANIP)

About ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals logoANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ANIP
  • CUSIP: N/A
  • Web: www.anipharmaceuticals.com
Capitalization:
  • Market Cap: $687.69 million
  • Outstanding Shares: 11,638,000
Average Prices:
  • 50 Day Moving Avg: $52.63
  • 200 Day Moving Avg: $48.79
  • 52 Week Range: $42.23 - $67.67
P/E:
  • Trailing P/E Ratio: 129.30
  • Foreward P/E Ratio: 12.96
  • P/E Growth: 1.06
Sales & Book Value:
  • Annual Revenue: $158.12 million
  • Price / Sales: 4.35
  • Book Value: $15.17 per share
  • Price / Book: 3.90
Profitability:
  • EBITDA: $59.01 million
  • Net Margins: 3.35%
  • Return on Equity: 22.70%
  • Return on Assets: 11.48%
Debt:
  • Debt-to-Equity Ratio: 0.87%
  • Current Ratio: 3.99%
  • Quick Ratio: 2.49%
Misc:
  • Average Volume: 108,908 shs.
  • Beta: 3.05
  • Short Ratio: 9.25
 

Frequently Asked Questions for ANI Pharmaceuticals (NASDAQ:ANIP)

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its earnings results on Thursday, August, 3rd. The company reported $0.98 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.79 by $0.19. The company had revenue of $44.80 million for the quarter, compared to analyst estimates of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The firm's quarterly revenue was up 43.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.11 EPS. View ANI Pharmaceuticals' Earnings History.

When will ANI Pharmaceuticals make its next earnings announcement?

ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for ANI Pharmaceuticals.

Where is ANI Pharmaceuticals' stock going? Where will ANI Pharmaceuticals' stock price be in 2017?

3 analysts have issued 1 year price targets for ANI Pharmaceuticals' stock. Their predictions range from $56.00 to $80.00. On average, they anticipate ANI Pharmaceuticals' share price to reach $67.33 in the next year. View Analyst Ratings for ANI Pharmaceuticals.

What are analysts saying about ANI Pharmaceuticals stock?

Here are some recent quotes from research analysts about ANI Pharmaceuticals stock:

  • 1. Canaccord Genuity analysts commented, "We remain pessimistic about the company’s ability to execute a successful clinical trial required for FDA approval. The planned 2018 $10M cost-cutting initiative suggests to us that Eagle isn’t too confident either (and is generally in line with our expectations). Eagle’s other pipeline programs like fulvestrant and drug-induced hyperthermia are questionable and may require a few more years of development under a best case scenario, in our view. There was strangely no mention of the Alimta RTD PDUFA in October. Eagle also reiterated prior 2017 expense guidance of $50-$53M in SG&A (excluding stock based comp) and $26- $30M R&D (excluding stock-based comp). We note the company was previously reporting GAAP earnings so the change is slightly new. We also note that Eagle has expanded its borrowing capacity by $100M (suggesting to us that it may want to bring in new assets) but simultaneously announced an additional $100M buyback program." (8/9/2017)
  • 2. According to Zacks Investment Research, "ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. " (7/5/2017)

Who are some of ANI Pharmaceuticals' key competitors?

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the folowing people:

  • Robert E. Brown Jr., Independent Chairman of the Board
  • Arthur S. Przybyl, President, Chief Executive Officer, Director
  • Stephen P. Carey, Chief Financial Officer, Vice President
  • James G. Marken, Vice President - Operations
  • Mark J. Ginski Ph.D., Vice President of Corticotropin Product Development
  • Karen Quinn Ph.D., Vice President - Corticotropin Regulatory Affairs
  • Robert W. Schrepfer, Vice President - New Business Development and Contract Manufacturing
  • Fred E. Holubow, Independent Director
  • Tracy L. Marshbanks Ph.D., Independent Director
  • Thomas A. Penn, Independent Director

How do I buy ANI Pharmaceuticals stock?

Shares of ANI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ANI Pharmaceuticals' stock price today?

One share of ANI Pharmaceuticals stock can currently be purchased for approximately $59.09.


MarketBeat Community Rating for ANI Pharmaceuticals (NASDAQ ANIP)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  306
MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ANI Pharmaceuticals (NASDAQ:ANIP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $67.33 (13.95% upside)
Consensus Price Target History for ANI Pharmaceuticals (NASDAQ:ANIP)
Price Target History for ANI Pharmaceuticals (NASDAQ:ANIP)
Analysts' Ratings History for ANI Pharmaceuticals (NASDAQ:ANIP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017Canaccord GenuityReiterated RatingBuy -> Buy$60.00 -> $66.00N/AView Rating Details
7/4/2017GuggenheimReiterated RatingBuy$80.00LowView Rating Details
5/6/2017Roth CapitalSet Price TargetHold$56.00LowView Rating Details
8/5/2016Oppenheimer Holdings, Inc.Boost Price TargetOutperform$65.00 -> $71.00N/AView Rating Details
7/19/2016Citigroup Inc.UpgradeOutperform$65.00N/AView Rating Details
6/22/2016Raymond James Financial, Inc.Initiated CoverageStrong-Buy$68.00N/AView Rating Details
5/24/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for ANI Pharmaceuticals (NASDAQ:ANIP)
Earnings by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
Earnings History by Quarter for ANI Pharmaceuticals (NASDAQ ANIP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017$0.99N/AView Earnings Details
8/3/2017Q2 2017$0.79$0.98$43.20 million$44.80 millionViewListenView Earnings Details
5/4/2017Q1 2017$0.70$0.74$39.63 million$36.60 millionViewListenView Earnings Details
3/2/2017Q4 2016$1.09$0.84$40.98 million$38.20 millionViewListenView Earnings Details
11/3/2016Q316$1.08$1.09$34.34 million$38.53 millionViewN/AView Earnings Details
8/4/2016Q216$0.77$1.11$27.63 million$31.30 millionViewN/AView Earnings Details
5/5/2016Q116$0.64$0.76$21.03 million$20.60 millionViewN/AView Earnings Details
2/23/2016Q415$0.60$0.52$18.13 million$18.04 millionViewN/AView Earnings Details
11/3/2015Q315$0.63$0.80$21.37 million$20.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.54$0.31$20.30 million$19.52 millionViewN/AView Earnings Details
5/5/2015Q115$0.56$0.53$19.86 million$18.80 millionViewN/AView Earnings Details
2/19/2015Q414$0.57$0.60$17.98 million$21.04 millionViewN/AView Earnings Details
11/3/2014Q314$0.43$0.59$14.60 million$17.40 millionViewN/AView Earnings Details
8/4/2014Q214($0.01)($0.21)$7.95 million$6.60 millionViewN/AView Earnings Details
5/5/2014Q115$0.32$0.33$11.40 million$10.90 millionViewN/AView Earnings Details
2/27/2014Q414$0.35$5.32 million$10.53 millionViewN/AView Earnings Details
11/7/2013$0.16ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ANI Pharmaceuticals (NASDAQ:ANIP)
Current Year EPS Consensus Estimate: $3.84 EPS
Next Year EPS Consensus Estimate: $4.56 EPS

Dividends

Dividend History for ANI Pharmaceuticals (NASDAQ:ANIP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ANI Pharmaceuticals (NASDAQ:ANIP)
Insider Ownership Percentage: 31.80%
Institutional Ownership Percentage: 55.81%
Insider Trades by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
Insider Trades by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2016Arthur PrzybylInsiderSell37,455$66.97$2,508,361.35View SEC Filing  
8/8/2016Robert W SchrepferVPSell12,500$67.06$838,250.00View SEC Filing  
12/18/2015James G MarkenVPSell3,500$43.26$151,410.00View SEC Filing  
11/12/2015Arthur PrzybylCEOBuy2,500$40.95$102,375.00View SEC Filing  
3/19/2015James G MarkenVPSell15,000$66.50$997,500.00View SEC Filing  
9/15/2014Ross J ManganoDirectorBuy3,000$27.49$82,470.00View SEC Filing  
9/9/2014Arthur PrzybylCEOBuy1,000$26.50$26,500.00View SEC Filing  
6/18/2014James G MarkenVPSell5,000$34.28$171,400.00View SEC Filing  
5/8/2014Tracy MarshbanksDirectorSell1,381$30.02$41,457.62View SEC Filing  
5/7/2014Ross ManganoDirectorBuy2,000$30.38$60,760.00View SEC Filing  
3/21/2014Tracy MarshbanksDirectorSell21,767$31.42$683,919.14View SEC Filing  
3/20/2014Meridian Venture Partners Ii Lmajor shareholderSell20,922$32.12$672,014.64View SEC Filing  
3/19/2014Tracy MarshbanksDirectorSell25,358$33.68$854,057.44View SEC Filing  
3/18/2014Meridian Venture Partners Ii Lmajor shareholderSell60,540$34.07$2,062,597.80View SEC Filing  
3/13/2014Meridian Venture Partners Ii Lmajor shareholderSell87,723$32.48$2,849,243.04View SEC Filing  
11/7/2013Ross J ManganoDirectorBuy9,000$11.27$101,430.00View SEC Filing  
8/20/2013Ross J ManganoDirectorBuy10,000$7.47$74,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ANI Pharmaceuticals (NASDAQ:ANIP)
Latest Headlines for ANI Pharmaceuticals (NASDAQ:ANIP)
Source:
DateHeadline
americanbankingnews.com logoHead-To-Head Survey: NovaBay Pharmaceuticals (NBY) and ANI Pharmaceuticals (ANIP)
www.americanbankingnews.com - October 20 at 8:34 PM
americanbankingnews.com logoFinancial Review: ANI Pharmaceuticals (ANIP) vs. The Competition
www.americanbankingnews.com - October 18 at 12:12 AM
nasdaq.com logoANIP Crosses Above Average Analyst Target
www.nasdaq.com - October 16 at 4:44 PM
finance.yahoo.com logoETFs with exposure to ANI Pharmaceuticals, Inc. : October 16, 2017
finance.yahoo.com - October 16 at 4:44 PM
americanbankingnews.com logoANI Pharmaceuticals, Inc. (ANIP) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 11 at 2:32 AM
americanbankingnews.com logoZacks: Analysts Expect ANI Pharmaceuticals, Inc. (ANIP) Will Announce Quarterly Sales of $48.46 Million
www.americanbankingnews.com - October 6 at 4:08 PM
americanbankingnews.com logo Analysts Anticipate ANI Pharmaceuticals, Inc. (ANIP) Will Post Earnings of $0.99 Per Share
www.americanbankingnews.com - October 4 at 4:32 AM
seekingalpha.com logoANI Pharmaceuticals' Hidden Value - Seeking Alpha
seekingalpha.com - October 3 at 3:39 PM
finance.yahoo.com logoETFs with exposure to ANI Pharmaceuticals, Inc. : October 3, 2017
finance.yahoo.com - October 3 at 3:39 PM
finance.yahoo.com logoANI Pharmaceuticals Inc (ANIP): Can It Deliver A Superior ROE To The Industry?
finance.yahoo.com - October 2 at 3:46 PM
finance.yahoo.com logoETFs with exposure to ANI Pharmaceuticals, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 8:57 PM
americanbankingnews.com logoANI Pharmaceuticals, Inc. (ANIP) Expected to Post Quarterly Sales of $48.46 Million
www.americanbankingnews.com - September 17 at 7:50 AM
americanbankingnews.com logoANI Pharmaceuticals, Inc. (ANIP) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 16 at 2:46 AM
americanbankingnews.com logo Analysts Anticipate ANI Pharmaceuticals, Inc. (ANIP) to Announce $0.99 EPS
www.americanbankingnews.com - September 15 at 12:30 PM
americanbankingnews.com logoHead-To-Head Review: Nabriva Therapeutics plc - (NBRV) vs. ANI Pharmaceuticals (ANIP)
www.americanbankingnews.com - September 12 at 8:28 PM
finance.yahoo.com logoETFs with exposure to ANI Pharmaceuticals, Inc. : September 7, 2017
finance.yahoo.com - September 7 at 3:55 PM
finance.yahoo.com logoANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
finance.yahoo.com - September 5 at 5:32 PM
streetinsider.com logoANI Pharma (ANIP) Reports FDA Approval and Launch of Oxycodone Hydrochloride Oral Solution 100 mg/5mL
www.streetinsider.com - September 3 at 1:45 AM
prnewswire.com logoANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL - PR Newswire (press release)
www.prnewswire.com - September 2 at 3:40 PM
nasdaq.com logoANI Pharma Reveals Approval And Launch Of Oxycodone Hydrochloride Oral Solution
www.nasdaq.com - September 1 at 4:26 PM
finance.yahoo.com logoANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL
finance.yahoo.com - September 1 at 4:26 PM
finance.yahoo.com logoANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US : September 1, 2017
finance.yahoo.com - September 1 at 4:26 PM
americanbankingnews.com logoReviewing OncoSec Medical (ONCS) and ANI Pharmaceuticals (ANIP)
www.americanbankingnews.com - August 31 at 4:26 AM
americanbankingnews.com logo$0.99 EPS Expected for ANI Pharmaceuticals, Inc. (ANIP) This Quarter
www.americanbankingnews.com - August 28 at 12:20 AM
americanbankingnews.com logoANI Pharmaceuticals, Inc. (ANIP) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 22 at 2:32 AM
nasdaq.com logoCompany Spotlight: ANI Pharmaceuticals - Nasdaq
www.nasdaq.com - August 19 at 2:05 AM
rttnews.com logoCompany Spotlight: ANI Pharmaceuticals
www.rttnews.com - August 18 at 4:02 PM
seekingalpha.com logoANI Pharmaceuticals Valued Cheaply Ahead Of Re-Commercialization Of Corticotropin Products
seekingalpha.com - August 17 at 5:20 PM
finance.yahoo.com logoANI Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ANIP) : August 16, 2017
finance.yahoo.com - August 16 at 9:08 PM
americanbankingnews.com logo$48.46 Million in Sales Expected for ANI Pharmaceuticals, Inc. (ANIP) This Quarter
www.americanbankingnews.com - August 11 at 4:00 PM
prnewswire.com logoANI Pharmaceuticals to Present at the Canaccord Genuity 37th Annual Growth Conference - PR Newswire (press release)
www.prnewswire.com - August 10 at 2:04 AM
americanbankingnews.com logoANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - August 9 at 9:44 PM
americanbankingnews.com logo$0.90 Earnings Per Share Expected for ANI Pharmaceuticals, Inc. (ANIP) This Quarter
www.americanbankingnews.com - August 9 at 2:12 PM
finance.yahoo.com logoETFs with exposure to ANI Pharmaceuticals, Inc. : August 8, 2017
finance.yahoo.com - August 8 at 8:48 PM
finance.yahoo.com logoANI Pharmaceuticals to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 8 at 3:46 PM
rttnews.com logoANI Pharmaceuticals, Inc. Profit Advances 32% In Q2
www.rttnews.com - August 4 at 10:04 PM
finance.yahoo.com logoEdited Transcript of ANIP earnings conference call or presentation 3-Aug-17 2:30pm GMT
finance.yahoo.com - August 4 at 10:04 PM
nasdaq.com logoANI Pharmaceuticals, Inc. Bottom Line Climbs 32% In Q2 - Nasdaq
www.nasdaq.com - August 4 at 4:18 PM
seekingalpha.com logoANI Pharmaceuticals' (ANIP) CEO Arthur Przybyl on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 3:24 AM
prnewswire.com logoANI Pharmaceuticals Reports Record Second Quarter and Year-To-Date 2017 Results and Reaffirms Guidance - PR Newswire (press release)
www.prnewswire.com - August 3 at 5:20 PM
nasdaq.com logoANI Pharmaceuticals, Inc. Profit Advances 32% In Q2 - Nasdaq
www.nasdaq.com - August 3 at 5:20 PM
finance.yahoo.com logoANI Pharmaceuticals Reports Record Second Quarter and Year-To-Date 2017 Results and Reaffirms Guidance
finance.yahoo.com - August 3 at 5:20 PM
finance.yahoo.com logoANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ANIP-US : August 3, 2017
finance.yahoo.com - August 3 at 5:20 PM
finance.yahoo.com logoANI posts 2Q profit
finance.yahoo.com - August 3 at 5:20 PM
americanbankingnews.com logoANI Pharmaceuticals, Inc. (ANIP) Announces Earnings Results, Beats Expectations By $0.12 EPS
www.americanbankingnews.com - August 3 at 3:38 PM
americanbankingnews.com logoANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 28 at 11:21 AM
americanbankingnews.com logoANI Pharmaceuticals, Inc. (ANIP) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - July 27 at 8:14 PM
prnewswire.com logoANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - July 27 at 3:35 PM
finance.yahoo.com logoANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2017 Financial Results
finance.yahoo.com - July 27 at 3:35 PM
americanbankingnews.com logo Brokerages Expect ANI Pharmaceuticals, Inc. (ANIP) Will Post Quarterly Sales of $43.70 Million
www.americanbankingnews.com - July 22 at 10:57 AM

Social

Chart

ANI Pharmaceuticals (ANIP) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.